Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression

NCT00322764 is registered in ClinicalTrials.gov with Repligen Corporation as lead sponsor.

NCT NCT00322764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression
Lead sponsor
Repligen Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
Not reported
Enrollment
80 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression